Bio-Path Holdings Provides 2024 Clinical and Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Roth/MKM Reiterates $40 PT on Bio-Path Holdings (BPTH): 'Business Update Includes Developing Prexigebersen For Obesity'
April 2, 2024 10:50 AM UTCRoth/MKM analyst Philip Shen reiterated a Buy rating and $40.00 price target on Bio-Path Holdings (NASDAQ: BPTH).
The analyst comments "BPTH outlined its business plan most notably by adding obesity and obesityrelated cancers to its prexigebersen development plans, a drug currently in Phase 2 development in AML. BPTH is... More
